Skip to main content
SpringerLink
Log in
Book cover

Bone Metastases pp 407–417Cite as

Assessment of Therapeutic Response Through Clinical Assessment Measures

  • Chapter
  • First Online:

Part of the book series: Cancer Metastasis - Biology and Treatment ((CMBT,volume 21))

Abstract

Bone metastases from advanced stage cancers are common. They pose a significant added burden on both the patient and the health care system as a whole. There has been extensive interest in developing new strategies to improve patient care in this area. Traditionally, trials have focused on the incidence and timing of skeletal-related events (SREs) to compare the efficacy of bone–targeted agents against placebo and against each other. However, there are fundamental issues with translating clinical trial data into widespread clinical care. As seen in clinical trials that tend to include patients with better performance status, enroll fewer patients with bone only disease, and use more bone imaging than is used in the real world setting. Therefore, we need more practical tools that will allow us to assess therapeutic response in the clinical setting. In reality, this will prove challenging, as so far we have been unable to combine commonly used clinical trial endpoints with endpoints that are pertinent to an individual patient in a pragmatic and validated manner. This chapter will review the common clinical outcome measures used to assess response and progression in patients with bone metastases.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Mercadante S (1997) Malignant bone pain: pathophysiology and treatment. Pain 69(1e2):1–18

    Article  PubMed  CAS  Google Scholar 

  2. Coleman RE (2006) Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Re 12:6243s–6249s

    Article  Google Scholar 

  3. Hayashi N, Yamauchi H (2012) Role of circulating tumour cells and disseminated tumor cells in primary breast cancer. Breast Cancer 19:110–117

    Article  PubMed  Google Scholar 

  4. Costelloe CM, Chuang HH, Madewell JE et al (2010) Cancer response criteria and bone metastases: RECIST 1.1, MDA and PERCIST. J Cancer 1:80–92

    Article  PubMed  Google Scholar 

  5. Hamaoka T, Madewell JE, Podoloff DA et al (2004) Bone imaging in metastatic breast cancer. J Clin Oncol 22:2942–2953

    Article  PubMed  Google Scholar 

  6. Camp A, Danson S, Nguyen H et al (2004) Assessment of therapeutic response in patients with metastatic bone disease. Lancet Oncol 5:607–616

    Article  Google Scholar 

  7. Kang H, Lee HY, Lee KS et al (2012) Imaging-based tumor treatment response evaluation: review of conventional, new, and emerging concepts. Korean J Radiol 13(4):371–390

    Article  PubMed  Google Scholar 

  8. Janicek M, Hayes D, Kaplan W (1994) Healing flare in skeletal metastases from breast cancer. Radiology 192:201–204

    PubMed  CAS  Google Scholar 

  9. Niikura N, Liu J, Hayashi N et al (2012) Retrospective analysis of antitumor effects of zoledronic acid in breast cancer patients with bone-only metastases. Cancer 118(8):2039–2047

    Article  PubMed  CAS  Google Scholar 

  10. Fallowfield LJ, Fleissig A (2012) The value of progression-free survival to patients with advanced-stage cancer. A Nat Rev Clin Oncol 9:41–47

    Article  CAS  Google Scholar 

  11. Coleman RE, Gnant M, Morgan G et al (2012) Adjuvant bone-targeted therapy to prevent metastases: lessons from azure study. JNCI J Natl Cancer Inst 104(14):1059–1067

    Article  CAS  Google Scholar 

  12. Miller AB, Hoogstraten B, Staquet M et al (1981) Reporting results of cancer treatment. Cancer 47:207–214

    Article  PubMed  CAS  Google Scholar 

  13. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247

    Article  PubMed  CAS  Google Scholar 

  14. Booth CM, Eisenhauer EA (2012) Progression-free survival: meaningful or simply measurable? J Clin Oncol 30(10):1030–1033

    Article  PubMed  Google Scholar 

  15. Verma S, McLeod D, Batist G et al (2011) In the end what matters most? A review of clinical endpoints in advanced breast cancer. Oncologist 16:25–35

    Article  PubMed  Google Scholar 

  16. Saad ED, Katz A, Hoff PM et al (2010) Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature. Ann Oncol 21:7–12

    Article  PubMed  CAS  Google Scholar 

  17. Dancey JE, Dodd LE, Ford R et al (2009) Recommendations for the assessment of progression in randomised cancer treatment trials. Eur J Cancer 45:281–289

    Article  PubMed  CAS  Google Scholar 

  18. Panageas KS, Ben-Porat L, Dickler MN et al (2007) When you look matters: the effect of assessment schedule on progression-free survival. J Natl Cancer Inst 99:428–432

    Article  PubMed  Google Scholar 

  19. Chakravarty A, Sridhara R (2008) Use of progression-free survival as a surrogate marker in oncology trials: some regulatory issues. Stat Methods Med Res 17:515–518

    Article  PubMed  Google Scholar 

  20. Bergmann L, Hirschfeld S, Morris C et al (2007) Progression-free survival as an end-point in clinical trials of biotherapeutic agents. Eur J Cancer Suppl 5:23–28

    Article  Google Scholar 

  21. Johnson JR, Williams G, Pazdur R (2003) End points and United States food and drug administration approval of oncology drugs. J Clin Oncol 21:1404–1411

    Article  PubMed  Google Scholar 

  22. Healey JH, Brown HK (2000) Complications of bone metastases: surgical management. Cancer 88:2940–2951

    Article  PubMed  CAS  Google Scholar 

  23. Bouganim N, Dranitsaris G, Amir E et al (2011) Optimising the use of bone-targeted agents in patients with metastatic cancers: a practical guide for medical oncologists. Support Care Cancer 19:1687–1696

    Article  PubMed  Google Scholar 

  24. Berenson JR, Lichtenstein A, Porter L et al (1998) Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia study group. J Clin Oncol 16:593–602

    PubMed  CAS  Google Scholar 

  25. Lipton A (2003) Bisphosphonates and metastatic breast carcinoma. Cancer 97(848):853

    Google Scholar 

  26. Lipton A, Theriault RL, Hortobagyi GN et al (2000) Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo controlled trials. Cancer 88:1082–1090

    Article  PubMed  CAS  Google Scholar 

  27. Rosen LS (2004) New generation of bisphosphonates: broad clinical utility in breast and prostate cancer. Oncology (Williston Park) 18:26–32

    Google Scholar 

  28. Saad F, Schulman CC (2004) Role of bisphosphonates in prostate cancer. Eur Urol 45:26–34

    Article  PubMed  CAS  Google Scholar 

  29. Coleman RE (2005) Bisphosphonates in breast cancer. Ann Oncol 16:687–695

    Article  PubMed  CAS  Google Scholar 

  30. Major PP, Cook RJ, Chen BL, et al (2004) Survival-adjusted cumulative event analysis of skeletal-related events in patients with cancer metastatic to bone in trials of zoledronic acid. Seventh workshop on bisphosphonates—from the laboratory to the patient. What is new in bisphosphonates?, 24–26 March 2004, Davos, Poster 71

    Google Scholar 

  31. Major PP, Cook R (2002) Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical end points. Am J Clin Oncol 25(Suppl 1):S10–S18

    Article  PubMed  Google Scholar 

  32. Andersen PK, Gill RD (1982) Cox’s regression model for counting processes: a large sample study. Ann Stat 10:1100–1120

    Article  Google Scholar 

  33. Clemons MJ, Dranitsaris G, Ooi WS et al (2006) Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. J Clin Oncol 24:4895–4900

    Article  PubMed  CAS  Google Scholar 

  34. Coleman RE, Rubens RD (1987) The clinical course of bone metastases from breast cancer. Br J Cancer 55:61–66

    Article  PubMed  CAS  Google Scholar 

  35. Norgaard M, Jensen AO, Jacobsen JB et al (2010) Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol 184:162–167

    Article  PubMed  Google Scholar 

  36. Yong M, Jensen AO, Jacobsen JB et al (2011) Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999–2007). Breast Cancer Res Treat 129:495–503

    Article  PubMed  Google Scholar 

  37. Galasko CSB (1981) The anatomy and pathways of skeletal metastases. In: Weiss L, Gilbert A (eds) Bone metastases. GK Hall, Boston, pp 49–63

    Google Scholar 

  38. Serafini AN (2001) Therapy of metastatic bone pain. J Nucl Med 42:895–906

    PubMed  CAS  Google Scholar 

  39. Matza LS, Fallowfield LJ, Chung KC et al (2012) Patient-reported outcome instruments used to assess pain and functioning in studies of bisphosphonate treatment for bone metastases. Support Care Cancer 4:657–677

    Article  Google Scholar 

  40. Amir E, Freedman O, Carlsson L et al (2012) Randomized feasibility study of de-escalated (every 12 wk) versus standard (every 3 to 4 wk) intravenous pamidronate in women with low-risk bone metastases from breast cancer. Am J Clin Oncol. Accessed 9 July 2012. [Epub ahead of print]

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Medical Oncology – Cancer Center, Ottawa Hospital Research Institute, 501 Smyth Road, Ottawa, K1H 8L6, ON, Canada

    C. Roy, C. L. Addison, S. Mazzarello, I. Kuchuk, B. Hutton & M. Clemons

Authors
  1. C. Roy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. L. Addison
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Mazzarello
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. I. Kuchuk
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B. Hutton
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Clemons
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Roy .

Editor information

Editors and Affiliations

  1. Radiation Oncology, Bank of Cyprus Oncology Centre, Nicosia, Cyprus

    Vassilios Vassiliou

  2. Dept. Radiation Oncology, University of Toronto Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

    Edward Chow

  3. Dept. Radiation Oncology, University of Patras Medical School, Patras, Greece

    Dimitrios Kardamakis

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Roy, C., Addison, C.L., Mazzarello, S., Kuchuk, I., Hutton, B., Clemons, M. (2014). Assessment of Therapeutic Response Through Clinical Assessment Measures. In: Vassiliou, V., Chow, E., Kardamakis, D. (eds) Bone Metastases. Cancer Metastasis - Biology and Treatment, vol 21. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-7569-5_22

Download citation

Publish with us

Policies and ethics

Search

Navigation